Table 3 Predictors of response to primary therapy in patients with hematologic malignancy and aspergillosis

Age (years), median (range)

59 (14–81)

52 (16–86)

–

Gender, male

60 (59)

143 (59)

Diagnosis of invasive aspergillosis

–

 Definite

22/100 (22)

83 (34)

 Probable

78/100 (78)

158 (66)

Type of IA infection ^a

< .0001

 Invasive pulmonary infection

84 (83)

202 (84)

0.12 (0.04, 0.34)

(< .0001)

 Disseminated infection

1 (1)

24 (10)

0.02 (< 0.01, 0.16)

(< .0001)

 Localized or sinus infection

16 (16)

15 (6)

Referent

Type of cancer

–

 Leukemia

66/98 (67)

189/240 (79)

 Lymphoma

23/98 (23)

43/240 (18)

 Myeloma

9/98 (9)

8/240 (3)

Transplantation within 1 year prior to infection

34 (34)

98/240 (41)

–

Type of transplantation within prior year

 Allogeneic transplant

27/34 (79)

86/98 (88)

 Autologous transplant

7/34 (21)

12/98 (12)

Graft vs Host Disease (GVHD)

18/27 (67)

64/86 (74)

–

Neutropenia (< 500 ANC) at onset of IA

31/94 (33)

126/237 (53)

–

Persistent neutropenia

30/79 (38)

92/231 (40)

Received immunotherapy

38/99 (38)

163/240 (68)

–

Received WBC transfusion

5/100 (5)

50/240 (21)

0.21 (0.05, 0.66)

0.005

Year of IA diagnosis/treatment

–

 1993–2004

32 (32)

154 (64)

 2005–2016

69 (68)

87 (36)

Prophylactic antifungal treatment prior to infection

23/100 (23)

89 (37)

–

Breakthrough

22/23 (96)

76/88 (86)

Primary therapy strategy

< .0001

 Diagnostic-driven therapy with voriconazole

32 (32)

12 (5)

Referent

 Empiric antifungal therapy without voriconazole

30 (30)

191 (79)

0.05 (0.02, 0.12)

(< .0001)

 Empiric antifungal therapy with voriconazole

39 (39)

38 (16)

0.41 (0.16, 1.02)

(0.06)